Postinor®-2 | Shim Clinic, STD CLINIC SINGAPORE™

• What You Should Know About Emergency Contraception

• Microgynon® 30
• Diane-35® has additional anti-androgen activity for acne control in females

Contraceptive injection Depo-Provera® is a convenient method of contraception for those who prefer not to take oral contraceptives. One dose is given once every three months. (Four times a year)

Transdermal Contraceptive patch Evra® is an innovative method of drug delivery for those who prefer not to take oral contraceptives.

• On the first day of menstruation, the first patch is applied.
• At the end of the first week, the first patch is replaced by the second patch.
• At the end of the second week, the second patch is replaced by the third patch.
• At the end of the third week, the third patch is removed, and is followed by one patch free week.
• The cycle is repeated with the onset of menstruation.

Intra-vaginal contraceptive ring, NuvaRing® is a very convenient method of contraception for those who prefer not to take oral contraceptives.

• On the first day of menstruation, the ring is inserted into place at the top of the vagina, around the cervix.
• After 21 days, the ring is removed and disposed off.
• The cycle is repeated with the onset of menstruation.

References

• Postinor 2 - Wikipedia, the free encyclopedia
• Postinor 2: Definition from Answers.com
• Postinor 2 - definition of Postinor 2 in the Medical dictionary - by the Free Online Medical Dictionary, Thesaurus and Encyclopedia.
• WHO | Contraception
• Contraception: Unintended and Teen Pregnancy | CDC Reproductive Health
• Evra® package insert

Progestin-Based IUD Not Linked to Weight Gain (CME/CE)
Sat, 12 May 2012 18:46:31 +0100 | MedPage Today OB/GYN
SAN DIEGO (MedPage Today) -- There was no significant difference in weight gain between users of a levonorgestrel-eluting intrauterine device (IUD) and users of a copper IUD, according to a small study. (Source: MedPage Today OB/GYN)

Clot risk of contraceptive patch examined
Fri, 11 May 2012 17:55:00 +0100 | NHS News Feed
Conclusion This large study provides valuable information on the rate of VTE that may be experienced among users of hormonal contraception. However, the findings are not completely surprising. Oestrogen-containing hormonal contraceptives are already known to increase the risk of VTE, and medical professionals already consider this potential side effect when prescribing contraception and monitoring patients. Instead of revealing some new or major danger, this study provides a good indication of how the risks compare for a variety of different contraceptive methods. The oestrogen-containing contraceptives currently available are the combined oral contraceptive ----, the transdermal patch (of which there is one licensed product – brand name Evra) and the vaginal ring (of which there is one...

LUTERA (Levonorgestrel And Ethinyl Estradiol) Kit [Physicians Total Care, Inc.]
Tue, 08 May 2012 05:00:00 +0100 | DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)
Updated Date: May 8, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Assessment of the use of two new low-dose levonorgestrel-releasing intrauterine systems as contraceptives
Thu, 03 May 2012 13:55:45 +0100 | Future Medicine: Women's Health
Women's Health , May 2012, Vol. 8, No. 3, Pages 235-238. (Source: Future Medicine: Women's Health)

PLAN B (Levonorgestrel) Tablet [Physicians Total Care, Inc.]
Thu, 26 Apr 2012 05:00:00 +0100 | DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)
Updated Date: Apr 26, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects
Mon, 23 Apr 2012 13:03:10 +0100 | European Journal of Clinical Pharmacology
Conclusions  These data further support previous observations that lersivirine is a weak CYP3A4 inducer, a weak inhibitor of glucuronidation, and a P-glycoprotein inhibitor. In both studies, lersivirine appeared to have a good safety and tolerability profile. Content Type Journal ArticleCategory Short CommunicationPages 1-6DOI 10.1007/s00228-012-1287-5Authors John Davis, Pfizer Global Research and Development, Sandwich, UKGrant Langdon, Pfizer Global Research and Development, Sandwich, UKGary Layton, Pfizer Global Research and Development, Sandwich, UKChew Lan Chong, Pfizer Clinical Research Unit, Raffles Hospital, Singapore, SingaporeMarie-Noella Ndongo, Pfizer Research Clinic, CHU Erasme/ULB University, Anderlecht, Brussels, BelgiumManoli Vourvahis, Pfizer Global Re...

Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.
Sat, 21 Apr 2012 18:17:34 +0100 | Cochrane Database of Systematic Reviews
CONCLUSIONS: Current evidence suggests no major differences in carbohydrate metabolism between different hormonal contraceptives in women without diabetes. We cannot make strong statements due to having few studies that compared the same types of contraceptives. Many trials had small numbers of participants and some had large losses. Many of the earlier studies had limited reporting of methods.We still know very little about women at risk for metabolic problems due to being overweight. More than half of the trials had weight restrictions as inclusion criteria. Only one small trial stratified the groups by body mass index (obese versus normal). PMID: 22513937 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Levonorgestrel-Releasing Intrauterine System Versus Laparoscopic Supracervical Hysterectomy for the Treatment of Heavy Menstrual Bleeding: A Randomized Study
Fri, 20 Apr 2012 14:31:41 +0100 | Journal of Women
Journal of Women's Health , Vol. 0, No. 0. (Source: Journal of Women)

Levonorgestrel-Releasing Intrauterine System Versus Laparoscopic Supracervical Hysterectomy for the Treatment of Heavy Menstrual Bleeding: A Randomized Study.
Fri, 20 Apr 2012 04:00:00 +0100 | Pain Physician
Conclusions: LNG-IUS can be considered as first option for the treatment of HMB unresponsive to drug therapy, and it is particularly suitable for women who want to preserve an acceptable menstrual flow. LSH may be considered the best surgical option in women with HMB unresponsive to any medical treatment. PMID: 22519705 [PubMed - as supplied by publisher] (Source: Pain Physician)

ABOUT TRUST ONLINE